Patricia P. Centeno

Patricia P. Centeno

Auto-generated profile, based on publicly available information

Patricia P. Centeno

Cancer Research UK Scotland Institute, Glasgow, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
PCPatricia P. Centeno
Patricia P. Centeno
AHAmanda Herberger
Amanda Herberger
HMHee-Chang Mun
Hee-Chang Mun
CTChialing Tu
Chialing Tu
ENEdward F. Nemeth
Edward F. Nemeth
DWDonald T. Ward
Donald T. Ward
Extracellular phosphate regulates its own renal excretion by eliciting concentration-dependent secretion of parathyroid hormone (PTH). However, the phosphate-sensing mechanism remains unknown and requires elucidation for understanding the aetiology of secondary hyperparathyroidism in chronic kidney disease (CKD). The calcium-sensing receptor (CaSR) is the main controller of PTH secretion and here we show that raising phosphate concentration within the pathophysiologic range for CKD significantly inhibits CaSR activity via non-competitive antagonism. Mutation of residue R62 in anion binding site-1 abolishes phosphate-induced inhibition of CaSR. Further, pathophysiologic phosphate concentrations elicit rapid and reversible increases in PTH secretion from freshly-isolated human parathyroid cells consistent with a receptor-mediated action. The same effect is seen in wild-type murine parathyroid glands, but not in CaSR knockout glands. By sensing moderate changes in extracellular phosphate concentration, the CaSR represents a phosphate sensor in the parathyroid gland, explaining the stimulatory effect of phosphate on PTH secretion.

24 April 2023 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
PCPatricia P. Centeno
Patricia P. Centeno
VPValeria Pavet
Valeria Pavet
RMRichard Marais
Richard Marais

1 August 2019 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
LBLenah S. Binmahfouz
Lenah S. Binmahfouz
PCPatricia P. Centeno
Patricia P. Centeno
ACArthur D. Conigrave
Arthur D. Conigrave
DWDonald T. Ward
Donald T. Ward
The calcium-sensing receptor (CaS) is the principal controller of extracellular calcium (Ca2+o) homeostasis and is inhibited in vitro and in vivo by protein kinase C (PKC)-mediated phosphorylation at CaRT888. However, PKC inhibition enhances signalling even in CaSs lacking Thr-888, suggesting that an additional inhibitory site exists. An apparently equivalent PKC regulatory site in metabotropic glutamate receptor-5 (Ser-839) aligns not with CaST888 but instead with CaSS875, not previously considered a PKC site. CaSS875A (non-phosphorylatable) exhibited significantly enhanced Ca2+o sensitivity of both intracellular Ca2+ mobilisation and extracellular signal-regulated kinase 1/2 (ERK1/2) activation, whereas the phosphomimetic CaSS875D mutant exhibited a loss of function. The CaSS875A/T888A double mutant exhibited even greater Ca2+o sensitivity than CaST888 alone, a response no longer enhanced by PKC inhibition. Finally, when expressed in CaS lacking its extracellular domain, the CaSS875A/T888A double mutation elicited maximal activation even under control conditions, but remained sensitive to negative allosteric modulation (NPS-2143) or Ca2+o removal. Therefore, we have now identified CaSS875 as the missing PKC phosphorylation site that, together with CaST888, shapes the CaS signalling that underpins Ca2+o homeostasis. Together with the inactive form of the CaS9s extracellular domain, these sites attenuate Ca2+o sensitivity to attain appropriate physiological Ca2+o sensing. SIGNIFICANCE STATEMENT The calcium-sensing receptor (CaS) controls whole body calcium homeostasis by regulating parathyroid hormone secretion and renal calcium reabsorption. CaS function can be inhibited upon phosphorylation by protein kinase C (PKC), principally but not exclusively at Thr-888. Here we provide evidence that Ser-875, a previously unrecognised PKC site in CaS, is an additional inhibitory phosphorylation site for the receptor.

5 December 2024 in Cancer Research
Verified
Journal Article
Open access
CFCatriona A. Ford
Catriona A. Ford
DKDana Koludrovic
Dana Koludrovic
PCPatricia P. Centeno
Patricia P. Centeno
MFMona Foth
Mona Foth
ETElpida Tsonou
Elpida Tsonou
ACAndrew D. Campbell
Andrew D. Campbell
Metastatic melanoma remains a major clinical challenge. Large-scale genomic sequencing of melanoma has identified bona fide activating mutations in RAC1, which are associated with resistance to BRAF-targeting therapies. Targeting the RAC1-GTPase pathway, including the upstream activator PREX2 and the downstream effector PI3Kβ, could be a potential strategy for overcoming therapeutic resistance, limiting melanoma recurrence, and suppressing metastatic progression. Here, we used genetically engineered mouse models and patient-derived BRAFV600E-driven melanoma cell lines to dissect the role of PREX2 in melanomagenesis and response to therapy. Although PREX2 was dispensable for the initiation and progression of melanoma, its loss conferred sensitivity to clinically relevant therapeutics targeting the MAPK pathway. Importantly, genetic and pharmacologic targeting of PI3Kβ phenocopied PREX2 deficiency, sensitizing model systems to therapy. These data reveal a druggable PREX2/RAC1/PI3Kβ signaling axis in BRAF-mutant melanoma that could be exploited clinically. Significance: Cotargeting the MAPK and the PREX2/RAC1/PI3Kβ pathways has remarkable efficacy and outperforms monotherapy MAPK inhibition in BRAF-mutant melanoma, supporting the potential of this combination therapy for treating metastatic melanoma.

18 December 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
GKGeorgios Kanellos
Georgios Kanellos
CGChiara Giacomelli
Chiara Giacomelli
ARAlexander Raven
Alexander Raven
NVNikola Vlahov
Nikola Vlahov
HJHu Jin
Hu Jin
OSOwen Sansom
Owen Sansom
Nucleophosmin (NPM1), a nucleolar protein frequently mutated in hematopoietic malignancies, is overexpressed in several solid tumors with poorly understood functional roles. Here, we demonstrate that Npm1 is upregulated after APC loss in WNT-responsive tissues and supports WNT-driven intestinal and liver tumorigenesis. Mechanistically, NPM1 loss induces ribosome pausing and accumulation at the 5’-end of coding sequences, triggering a protein synthesis stress response and p53 activation, which mediate this antitumorigenic effect. Collectively, our data identify NPM1 as a critical WNT effector that sustains WNT-driven hyperproliferation and tumorigenesis by attenuating the integrated stress response and p53 activation. Notably, NPM1 expression correlates with elevated WNT signaling and proliferation in human colorectal cancer (CRC), while CRCs harboring NPM1 deletions exhibit preferential TP53 inactivation, underscoring the clinical relevance of our findings. Being dispensable for adult epithelial homeostasis, NPM1 represents a promising therapeutic target in p53-proficient WNT-driven tumors, including treatment-refractory KRAS -mutant CRC, and hepatic cancers.

8 January 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
PCPatricia P. Centeno
Patricia P. Centeno
CCChristopher Chester
Christopher Chester
GKGeorgios Kanellos
Georgios Kanellos
CFCatriona A. Ford
Catriona A. Ford
PCPatrizia Cammareri
Patrizia Cammareri
OSOwen J. Sansom
Owen J. Sansom
The continuous renewal of the skin relies on stem and progenitor cells, yet their differential susceptibility to oncogenic mutations in cutaneous squamous cell carcinoma (cSCC) remains unclear. Rapid cSCC develops in melanoma patients on BRAF inhibitors due to paradoxical MAPK activation. To model this in mice, we use two complementary approaches: HRAS G12V with a BRAF inhibitor to mimic paradoxical MAPK activation, and BRAF V600E , which drives MAPK hyperactivation without further treatment. We target these mutations to the interfollicular stem and differentiation-committed progenitors of the basal epidermis. While stem cells rapidly form tumours, progenitors exhibit long-latency resistance despite retaining mutations and repopulating the basal layer. Ultimately, both populations produce similar tumours, showing a shared transformation process. However, SOX2 is uniquely upregulated in progenitor-derived tumours and is expressed in 20% of human cSCC, indicating it might mark tumours arising from committed progenitors. Here, we show that SOX2 overexpression, along with MAPK activation, in progenitors induces a stem-like state and renders this otherwise resistant population permissive to rapid transformation.